We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...

Karyopharm Therapeutics Inc. (KPTI), a company focused on novel cancer therapies, said on Thursday that it has appointed Lori ...

Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Uber, Amazon and Ford are reportedly among the companies that have pledged to give $1 million to the 2025 inauguration.

Google's 2024 was all about AI. It was also a big year for shuffling in the executive ranks.

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

Eli Lilly shares have risen 30% so far this year, and were trading down about 1% at $758.90. Shares of Danish drugmaker Novo Nordisk (NOVOb.CO) have risen 10.6% this year and were trading 3.5% ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...